Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin 5mg vs 20mg for Carotid Plaque Regression
NCT02305862Unknown
- Sponsor
- Capital Medical University
- Start
- Jan 2013
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of rosuvastatin in carotid atheroma (CAS) and hyperlipidemia (2 arms), sponsored by Capital Medical University. Primary endpoint: Regression of carotid atherosclerotic plaques as measured by CE-MRI at 26 weeks. Status: unknown.
02
Drugs
rosuvastatin
03
Conditions
carotid atheroma (CAS)hyperlipidemia
Beyond the preview
Go deeper on NCT02305862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305862.